Skip to content

Study on early diagnosis of chronic obstructive pulmonary disease

Study on early diagnosis of chronic obstructive pulmonary disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDT-13003549
Enrollment
Unknown
Registered
2013-09-03
Start date
2013-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

Gold Standard:
Index test:

Sponsors

State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 40-85 yrs, both male and female, with or without smoking history, receiving treatment in community hospitals or outpatient department in general hospitals; (2) GOLD Stage I-II COPD: FEV1/FVC=50% predicted, measured 20min after 400ug salbutamol inhalation; (3) With stable COPD: no COPD exacerbation during the latest 4 weeks prior to the recruitment; (4) With capability of communicating via oral conversation or written documents and signing informed consent and with agreement to receive and are capable of participating in study related auxiliary examinations.

Exclusion criteria

Exclusion criteria: (1) Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the patients ability to participate in the study; (2) Patients with clinical diagnosis of lung cancer, bronchiectasis, pneumoconioses, or other single restricted ventilation; (3) Severe cardiovascular, neural, hepatic, renal and hematologic diseases or malignancies that may interfere with the operation of the study; (4) Patients with history of asthma, allergic rhinitis; (5) With the pulmonary rehabilitation treatment within 6 months.

Design outcomes

Primary

MeasureTime frame
cardiopulmonary exercise test ;

Secondary

MeasureTime frame
pulmonary function test;

Countries

China

Contacts

Public ContactPX.RAN

State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Diseases,First Affiliated Hospital, Guangzhou

pxrsn@vip.163.com+86 13922765811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026